Supernus Pharmaceuticals ( SUPN ) Surpasses Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +23.17% and +5.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
Analysts Estimate Amphastar Pharmaceuticals ( AMPH ) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma ( BBIO ) Reports Q3 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -7.95% and +14.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Supernus Pharmaceuticals ( SUPN ) is a Great Momentum Stock to Buy
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Earnings Preview: Supernus Pharmaceuticals ( SUPN ) Q3 Earnings Expected to Decline
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma ( BBIO ) Soars 17.1%: Is Further Upside Left in the Stock?
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Supernus Pharmaceuticals, Inc. ( SUPN ) Hits Fresh High: Is There Still Room to Run?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key
Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.
Why Supernus ( SUPN ) is Poised to Beat Earnings Estimates Again
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 - Supernus Pharmaceuticals ( NASDAQ:SUPN )
ROCKVILLE, Md., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, today announced that the Company expects to report ...
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
ROCKVILLE, Md., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, today announced that the Company expects to report ...
Global Anti-Parkinson's Drugs Markets Projected to Reach $9.2 Billion by the End of 2030
Boston, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, "Anti-Parkinson's Drugs: Global Markets to 2030" is projected to grow from $6.1 billion in 2025 to $9.2 billion by the end of 2030, at a compound annual growth rate ( CAGR ) of 8.6% from 2025 to 2030.
Can 4 Relative Price Strength Stocks Defy Market Swings?
UNFI, TDOC, SUPN and BRP shine with strong relative price strength, earnings momentum, and analyst upgrades amid volatile markets.
Supernus Pharmaceuticals ( SUPN ) Is Up 2.81% in One Week: What You Should Know
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?
Biogen's new drugs Leqembi, Skyclarys and Zurzuvae are driving fresh momentum, but MS and Spinraza declines cloud its growth path.
Supernus Pharmaceuticals, Inc. ( SUPN ) Hits Fresh High: Is There Still Room to Run?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday - Bloom Energy ( NYSE:BE ) , Citizens Financial Group ( NYSE:CFG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised Supernus Pharmaceuticals Inc ( NASDAQ:SUPN ) price target from $40 to $65.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Are You Looking for a Top Momentum Pick? Why Supernus Pharmaceuticals ( SUPN ) is a Great Choice
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Supernus Pharmaceuticals, Inc. ( SUPN ) Hit a 52 Week High, Can the Run Continue?
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Biogen Gets EU Nod for First Postpartum Depression Drug
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
Biogen Receives European Commission Approval for ZURZUVAE® ( zuranolone ) , the First and Only Treatment Approved for Women with Postpartum Depression in Europe - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Biogen ( NASDAQ:BIIB )
Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11
Biogen Receives European Commission Approval for ZURZUVAE® ( zuranolone ) , the First and Only Treatment Approved for Women with Postpartum Depression in Europe
CAMBRIDGE, Mass., Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced that the European Commission ( EC ) has granted marketing authorization for ZURZUVAE® ( zuranolone ) to treat post-partum depression ( PPD ) in adults following childbirth.
Controlled Release Drug Delivery Market Size FDA Approved Drugs Clinical Trials Companies Report 2030
Delhi, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales and Clinical Trials Insight 2030 Report Finding and Highlights: Global Market Current Size Insight In US$ Billion: 2022 - 2030 Global Market Opportunity: > US$ 90 Billion
Supernus Pharmaceuticals to Participate in September Investor Conferences - Supernus Pharmaceuticals ( NASDAQ:SUPN )
ROCKVILLE, Md., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, announced today management will participate in the following ...
Supernus Pharmaceuticals to Participate in September Investor Conferences
ROCKVILLE, Md., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, announced today management will participate in the ...
Insider Decision: Frederick Hudson Offloads $315K Worth Of Supernus Pharmaceuticals Stock - Supernus Pharmaceuticals ( NASDAQ:SUPN )
Making a noteworthy insider sell on August 18, Frederick Hudson, Director at Supernus Pharmaceuticals SUPN, is reported in the latest SEC filing. What Happened: Hudson's decision to sell 7,457 shares of Supernus Pharmaceuticals was revealed in a Form 4 filing with the U.S.
Supernus Pharmaceuticals ( SUPN ) Surpasses Q2 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +93.62% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Sage ( SAGE ) Q2 Revenue Jumps 264%
Sage Therapeutics ( NASDAQ:SAGE ) , a biopharmaceutical company focused on developing medicines for brain health disorders, released its second quarter 2025 results on July 30, 2025. The most important news from the quarter was the significant revenue beat, as sales reached $31.7 million ( GAAP ) ...
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Sage Therapeutics ( NASDAQ:SAGE )
ROCKVILLE, Md., July 31, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. SUPN ( "Supernus" ) today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. SAGE ( "Sage" ) .
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® ( zuranolone ) , and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base Acquisition ...
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Sage Therapeutics ( NASDAQ:SAGE )
ROCKVILLE, Md., July 28, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc., a Delaware corporation SUPN ( "Supernus", and the "Company" ) , today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ( "HSR Act" ) , with ...
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
ROCKVILLE, Md., July 28, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc., a Delaware corporation ( NASDAQ: SUPN ) ( "Supernus", and the "Company" ) , today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ( "HSR Act" ...
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
ROCKVILLE, Md., July 22, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, today announced that the Company expects to report ...
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. ( NASDAQ: SAGE )
NEW YORK, July 01, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. ( Nasdaq - VERV ) , Sage Therapeutics, Inc. ( Nasdaq - SAGE ) , Cantaloupe, Inc. ( Nasdaq - CTLP ) , Volato Group, Inc. ( NYSE American - SOAR )
BALA CYNWYD, Pa., June 27, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, CHTR, SAGE, TASK on Behalf of Shareholders - Charter Communications ( NASDAQ:CHTR ) , Guaranty Bancshares ( NYSE:GNTY )
NEW YORK, June 25, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Guaranty Bancshares, Inc.
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Sage Therapeutics ( NASDAQ:SAGE )
Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. ( Nasdaq - VERV ) , Sage Therapeutics, Inc. ( Nasdaq - SAGE ) , Cantaloupe, Inc. ( Nasdaq - CTLP ) , Volato Group, Inc. ( NYSE American - SOAR )
BALA CYNWYD, Pa., June 17, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Sage Therapeutics ( SAGE ) Soars 35.4%: Is Further Upside Left in the Stock?
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Sage Therapeutics ( NASDAQ:SAGE ) , Regencell Bioscience ( NASDAQ:RGC )
As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June - Robin Energy ( NASDAQ:RBNE ) , LZ Technology Hldgs ( NASDAQ:LZMH )
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 1% on Monday. The Dow traded up 0.80% to 42,536.72 while the NASDAQ climbed 1.51% to 19,699.21. The S&P 500 also rose, gaining, 0.97% to 6,034.20. Financial shares jumped by 1.7% on Monday.
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Advanced Micro Devices ( NASDAQ:AMD ) , AIRO Group Holdings ( NASDAQ:AIRO )
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Monday. Shares of Sage Therapeutics, Inc. SAGE rose sharply during Monday's session after Supernus Pharmaceuticals agreed to acquire the company.
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal - Sage Therapeutics ( NASDAQ:SAGE ) , Biogen ( NASDAQ:BIIB )
Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million.
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Sage Therapeutics ( NASDAQ:SAGE )
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® ( zuranolone ) , and a novel CNS discovery platform.
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) and Sage Therapeutics, Inc. ( Nasdaq: SAGE ) , today announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash ( or an ...
